Immunoassays — diagnostic tests that use antibody-antigen binding to detect and quantify specific molecules in biological samples — form the backbone of modern clinical laboratory medicine, pharmaceutical drug development, and research biomarker analysis. Among immunoassay formats, the singleplex immunoassay — designed to detect a single analyte with maximum sensitivity and specificity — occupies a critical position in both high-volume clinical diagnostics and specialized research applications requiring uncompromised analytical precision. The Singleplex Immunoassay Market — valued at approximately USD 209 million to USD 3.5 billion in 2025 (depending on market scope definition) and growing at a CAGR of 3.5–6.0% — is a foundational component of the global in vitro diagnostics industry.

What Is a Singleplex Immunoassay and Why Does It Matter?

A singleplex immunoassay measures a single specific analyte — a hormone, protein, antibody, antigen, drug, or other biomolecule — in a biological sample such as serum, plasma, urine, or CSF. Common singleplex formats include:

• ELISA (Enzyme-Linked Immunosorbent Assay) — The most widely used format; well-plate-based competition or sandwich architecture measuring analyte concentration via enzymatic color change
• CLIA (Chemiluminescence Immunoassay) — Used extensively on high-throughput automated analyzer platforms (Roche Elecsys, Abbott Architect, Siemens Atellica); superior sensitivity to enzyme-based ELISA for many clinical analytes
• FIA (Fluorescence Immunoassay) — High sensitivity through fluorescent labeling; used in both research and point-of-care applications
• RIA (Radioimmunoassay) — Gold-standard sensitivity for specific analytes (insulin, cortisol); declining use due to radioactive handling requirements

Nearly 68% of laboratories prefer singleplex assays for clinical applications due to their ability to deliver highly specific biomarker detection with minimal cross-reactivity — a precision advantage over multiplex formats when the clinical question concerns a specific analyte with regulatory-grade accuracy requirements.

Clinical Diagnostics: The Largest Application

Clinical diagnostics represents the largest singleplex immunoassay application segment, encompassing:

Cardiac biomarkers — Troponin I/T, BNP, NT-proBNP for myocardial infarction and heart failure diagnosis and risk stratification. High-sensitivity troponin assays (hs-Tn) — requiring exceptional analytical precision — are quintessential singleplex applications where analytical interference from other analytes is unacceptable. Beckman Coulter launched a fully automated BD-Tau research use only immunoassay in September 2025, expanding singleplex assay capability in neurodegenerative disease biomarker testing.

Endocrinology — TSH, free T4, insulin, cortisol, estradiol, testosterone, and growth hormone measurements are primarily performed as singleplex assays on high-throughput automated analyzers. These constitute extremely high-volume laboratory workloads globally.

Infectious disease serology — HIV antigen/antibody, hepatitis B/C serology, CMV IgG/IgM, and COVID-19 antibody/antigen testing are performed as singleplex assays in blood banks, clinical labs, and epidemiological surveillance programs.

Therapeutic drug monitoring — Immunosuppressant (cyclosporine, tacrolimus), antiepileptic, and antidepressant drug level monitoring uses singleplex formats for precise quantification of specific drugs in patient samples.

In October 2025, Roche extended its diagnostics portfolio with new Elecsys assays including pTau181 and cobas mass spectrometry offerings — illustrating the continued clinical expansion of singleplex immunoassay into emerging biomarker categories like Alzheimer's disease blood-based diagnostics.

Pharmaceutical Research: The Drug Development Engine

More than 60% of biopharmaceutical companies utilize singleplex immunoassays during drug development for biomarker validation, PK/PD analysis, and safety and efficacy assessment. Clinical trial immunogenicity testing — measuring patient antibody responses to biologic drugs — is predominantly performed using singleplex ELISA or electrochemiluminescence (ECL) formats that provide regulatory-acceptable sensitivity and specificity for anti-drug antibody detection.

In September 2024, key reagent manufacturers expanded partnerships with pharmaceutical developers to integrate automated singleplex immunoassay systems into drug-discovery workflows — reflecting the strategic importance of immunoassay automation in accelerating preclinical to clinical biomarker translation.

Key Players and Technology Landscape

The singleplex immunoassay market is led by Abbott Laboratories (Architect and Alinity platforms), Roche Diagnostics (Elecsys/cobas), Siemens Healthineers (Atellica), Beckman Coulter (Access/DxI), Thermo Fisher Scientific, Bio-Rad Laboratories, DiaSorin, Ortho Clinical Diagnostics (Ortho Vision Max), PerkinElmer (DELFIA), Agilent, and Quidel Corporation. Consumables (reagents, kits, antibodies, microplates) account for approximately 60–65% of market revenue, driven by recurring demand across both clinical and research settings.

In March 2025, major diagnostics firms launched high-sensitivity single-analyte assay kits tailored for clinical and research use — continuing the market trend toward improved analytical performance and broader biomarker coverage.

FAQ

What is the difference between singleplex and multiplex immunoassays? Singleplex assays measure one analyte per reaction, maximizing sensitivity, specificity, and standardization. Multiplex assays measure multiple analytes simultaneously, offering throughput efficiency. Singleplex is preferred when regulatory-grade precision for a specific analyte is required; multiplex is preferred for broad biomarker profiling in research settings where sample volume is limited.

Is ELISA still clinically relevant in the age of high-throughput analyzers? Yes. While automated CLIA analyzers dominate high-volume clinical laboratory testing, ELISA remains extensively used in research laboratories, academic institutions, and specialized clinical applications. Its flexibility, cost-effectiveness, and broad reagent availability ensure continued relevance alongside automated platforms.

What is driving singleplex immunoassay growth in neurodegenerative disease? The development of blood-based biomarkers for Alzheimer's disease (phospho-tau 181, amyloid-beta 42/40 ratio, neurofilament light chain) is creating new high-value singleplex clinical assay markets. These assays require extraordinary analytical sensitivity (detecting femtomolar concentrations in blood) achievable through ultra-sensitive singleplex platforms like Quanterix Simoa and Roche Elecsys.

#SingleplexImmunoassay #SingleplexImmunoassayMarket #ELISA #ClinicalDiagnostics #Immunoassay #BiomarkerDetection #InVitroDiagnostics #PharmaceuticalResearch #DiagnosticTesting